ArticleIrish journal of medical science2025
The ıncidence of neuropathic pain and ıts ımpact on quality of life in patients with lipedema.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Inter-Rater Reliability of the Progressive Pain Check Method for Standardized Pain Assessment in Lipedema.Life (Basel, Switzerland) · 2026Article
- Comorbidities in lipedema: toward a systemic perspective - a narrative review.Clinical and experimental medicine · 2026Review
- Objective measures of physical activity and physical capacities in lipedema - a scooping review.BMC women's health · 2026Article
- Lipedema as a hormone-sensitive stromal disorder: a four-pathway translational framework.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the frequency of neuropathic pain in patients with lipedema and to assess the impact of neuropathic pain on quality of life and its correlation with clinical variables.
methodThe prospective, descriptive study included 150 patients diagnosed with lipedema. The demographic characteristics, pain intensity, lipedema type, lipedema stage, and quality of life of the patients were evaluated. The during activity pain intensity was evaluated using the Visual Analogue Scale (VAS), and neuropathic pain was evaluated with the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale. Quality of life was assessed using the World Health Organization Quality of Life Scale Brief Version (WHOQOL-BREF).
resultsThis mean age of the patients was 42.63 ± 10.03 years, and the mean body mass index was 33.07 ± 5.67 kg/m2. Type 2 and stage 2 lipedema were present in 96% and 51.3% of the patients, respectively. The mean VAS score for pain in lipedema patients was 6.38 ± 1.71, and the mean LANSS score was 11.57 ± 7.11. The prevalence of neuropathic pain was 43.3%. Patients with neuropathic pain had statistically significantly higher VAS and LANSS scores (p = 0.001 and p < 0.001, respectively). The neuropathic pain group, scores for the physical and psychological domains of the WHOQOL-BREF were statistically significantly lower (p = 0.001 and p < 0.001, respectively).
conclusionsNearly half of the patients with lipedema have neuropathic pain, and neuropathic pain, which adversely affects the quality of life. Treatment should be planned in the presence of neuropathic pain in this patient group, in whom the etiopathogenesis of pain is not yet clearly known.
Indexed as
Identifiers
40788448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.